Inmunova
Buenos Aires, Argentina· Est.
Argentinian biotech developing a first‑in‑class anti‑Shiga toxin therapy for HUS.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Argentinian biotech developing a first‑in‑class anti‑Shiga toxin therapy for HUS.
Infectious DiseasesRare Diseases
Technology Platform
Protein and antibody engineering to produce polyclonal F(ab')2 fragments that neutralize multiple Shiga toxin variants, combined with vaccine and immunogen design capabilities.
Opportunities
Successful Phase 3 data could position INM004 as the first approved HUS therapy, enabling rapid market entry in Argentina and orphan‑drug pathways in Europe and the US, while the F(ab')2 platform may be extended to other toxin‑mediated diseases.
Risk Factors
Clinical trial failure, regulatory delays, and limited financial resources for large‑scale commercialization could impede progress; the niche market size may restrict revenue potential.
Competitive Landscape
No approved HUS treatments exist, giving Inmunova a first‑mover advantage; competition is limited to supportive care and early‑stage anti‑toxin programs from other biotech firms.